2026 ICD-10-CM Diagnosis Code T45.AX6AUnderdosing of immune checkpoint inhibitors and immunostimulant drugs, initial encounter
T45.AX6A is a billable ICD-10-CM diagnosis code for underdosing of immune checkpoint inhibitors and immunostimulant drugs, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Underdosing of drugs and medicaments, initial encounter.
Code Identity
Code Classification
Coding GuidelinesGuidance
Underdosing refers to taking less of a medication than is prescribed by a provider or a manufacturer's instruction. Codes for underdosing should never be assigned as principal or first-listed codes. If a patient has a relapse or exacerbation of the medical condition for which the drug is prescribed because of the reduction in dose, then the medical condition itself should be coded.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified (T45). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
| Substance | Accidental | Self-harm | Assault | Undetermined | Adverse Effect | Underdosing |
|---|---|---|---|---|---|---|
| Immune | T45.AX1 | T45.AX2 | T45.AX3 | T45.AX4 | T45.AX5 | T45.AX6 |
| Immune::checkpoint inhibitors | T45.AX1 | T45.AX2 | T45.AX3 | T45.AX4 | T45.AX5 | T45.AX6 |
| Immune::globulin | T45.AX1 | T45.AX2 | T45.AX3 | T45.AX4 | T45.AX5 | T45.AX6 |
| Immune::serum globulin | T45.AX1 | T45.AX2 | T45.AX3 | T45.AX4 | T45.AX5 | T45.AX6 |
| Immunostimulant drug | T45.AX1 | T45.AX2 | T45.AX3 | T45.AX4 | T45.AX5 | T45.AX6 |
Code History & ChangesHistory
Replacement T45.AX6A replaces the following previously assigned code(s):
- T45.1X6A - Underdosing of antineoplastic and immunosup drugs, init
Questions About T45.AX6AOverview
Is T45.AX6A a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report underdosing of immune checkpoint inhibitors and immunostimulant drugs, initial encounter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character A in T45.AX6A mean?
The final character A marks the initial encounter: use it while the patient is receiving active treatment for underdosing of immune checkpoint inhibitors and immunostimulant drugs, such as an emergency visit or first evaluation.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
